Posted inCardiology Clinical Updates
Eplontersen’s Modest Benefits on Cardiac Remodeling in Transthyretin Amyloidosis with Cardiomyopathy: Insights from the CARDIO-TTRansform Trial
In the CARDIO-TTRansform trial, eplontersen showed modest attenuation of cardiac structural deterioration and functional decline in transthyretin amyloidosis with cardiomyopathy, especially in patients not treated with TTR stabilizers at baseline.
